By Eric Sagonowsky,Annalee Armstrong,Max Bayer,Angus Liu
As the biopharma industry develops increasingly specialized treatments, regulators are being forced to adapt. And at the same time, the industry is making strides toward becoming more inclusive. These are the most influential regulators and advocates in biopharma.
read more
By Annalee Armstrong
Fierce Biotech is once again seeking your nominations for the best, most exciting and innovative private biotechs.
read more
By Robert King
Mayo Clinic posted a $227 million net loss for the first quarter of 2022 as the system faced major headwinds from rising labor expenses to a volatile investment market.
read more
By Zoey Becker
Patients with eosinophilic esophagitis have been suffering with no hope for relief as there are no FDA-approved treatments for the disease. That's now changed with an FDA nod for Sanofi's Dupixent.
read more
By Conor Hale
Vibrant Gastro is putting forward its novel approach as a completely drug-free alternative to treatments for infrequent or difficult bowel movements.
read more
By Cameron Evans
Blue Cross Blue Shield of Massachusetts launched a new program that will provide financial, strategic and mentorship support to startup founders of color focused on creating equitable healthcare services and solutions.
read more
By Max Bayer
Biohaven reported that troriluzole has failed a phase 3 trial in spinocerebellar ataxia, just weeks after CEO Vlad Coric, M.D., touted the company's future as a slimmed-down R&D engine after the migraine business was sold off to Pfizer for $11.6 billion.
read more
By Fraiser Kansteiner
A potential strike by more than 1,000 GSK engineers, technicians, lab analysts, warehouse workers and others has been called off after the employees—represented by Britain and Ireland’s biggest labor union Unite—accepted an improved pay offer from the British Big Pharma.
read more
By Conor Hale
The Revita DMR outpatient procedure strips out and helps reset the small intestine's lining, which can thicken over years from dietary fats, sugars and other foods.
read more
By Anastassia Gliadkovskaya
The program’s goal, according to the announcement, is to develop care services and improve outcomes.
read more
By Max Bayer
Precision BioSciences boasted two sets of early preclinical data of its gene editing platform at ASGCT, making its case over CRISPR. Notably, the company said it was able to make an insertion in the genome in non-human primates using its treatment for ornithine transcarbamylase deficiency.
read more
By Conor Hale
Pending FDA approval, HistoSonics will use guided sonic beams to deliver vibrations into the organ without breaking the skin, causing the targeted tissue to break down and liquify.
read more
By Nick Paul Taylor
Concert Pharmaceuticals has hit the high notes in a phase 3 alopecia areata clinical trial, finding 41.5% of people had at least 80% scalp hair coverage after taking the high dose of its JAK inhibitor. The data put Concert in the wings as Eli Lilly and Pfizer prepare to take to the stage and compete for the market.
read more
